CD9 and carcinoma: An emerging consensus is that α6β4 complex synergizes with specific molecules such as ErbB2, EGFR, Ron, Fyn, c-Met, protein kinase C, CD151, and CD9 to activate key signaling pathways for the invasion and migration of carcinoma cells via activation of signaling molecules such as PI3K [36], [37].